{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T21:40:57Z","timestamp":1768686057091,"version":"3.49.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Immunoglobulins are 2nd or 3rd-line treatments in dermatomyositis (DM) or polymyositis (PM) refractory to high-dose corticosteroids and immunosuppressants. Immunoglobulins (2\u200ag\/kg\/mo) are usually administered intravenously (IVIg) once a month and the patients stay at hospital for a few days. Recently, subcutaneous injections (SCIg) were proposed 2 to 3 times per week, in some dysimmune diseases. SCIg are administered at home preferably by the patient or by a nurse. We investigated the needs and attitudes of DM and PM patients with experience of IVIg and SCIg.<\/jats:p>\n            <jats:p>Seven patients (6 PM and 1 DM) from a single center participated in a focus group (N\u200a=\u200a6) or underwent in-depth interview (N\u200a=\u200a1). Six had the experience of both IVIg at hospital and SCIg at home; 1 has received only IVIg at hospital. Verbatim was recorded and transcribed for further content analysis and computer-aided textual analysis.<\/jats:p>\n            <jats:p>Clinical profiles and stories were heterogeneous. At diagnosis, muscle weakness, severe pain, and fatigue were at the forefront of patients\u2019 complaints impairing daily life. Patients reported considerable improvement with immunoglobulins. SCIg were described as easy, less disruptive for daily life, well tolerated, and less time-consuming. SCIg self-administration at home restored the feeling of autonomy and control.<\/jats:p>\n            <jats:p>Interviews of DM and PM patients revealed that recovering autonomy and control was a central advantage of home-based SCIg that were efficient, well tolerated, and perceived as a good compromise between treatment burden and efficacy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000019012","type":"journal-article","created":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T20:10:43Z","timestamp":1581538243000},"page":"e19012","source":"Crossref","is-referenced-by-count":12,"title":["Recovering autonomy is a key advantage of home-based immunoglobulin therapy in patients with myositis"],"prefix":"10.1097","volume":"99","author":[{"given":"Patrick","family":"Ch\u00e9rin","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Clinical Immunology, La Piti\u00e9 Salp\u00e9tri\u00e8re Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taylor","family":"Pindi Sala","sequence":"additional","affiliation":[{"name":"University Paris-Diderot, Patient-Centered Outcomes Research, Paris"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Clerson","sequence":"additional","affiliation":[{"name":"Soladis Clinical Studies, Roubaix"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna\u00efk","family":"Dokhan","sequence":"additional","affiliation":[{"name":"Sirius Customizer, Paris"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yann","family":"Fardini","sequence":"additional","affiliation":[{"name":"Soladis Clinical Studies, Roubaix"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Duracinsky","sequence":"additional","affiliation":[{"name":"University Paris-Diderot, Patient-Centered Outcomes Research, Paris"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Charles","family":"Crave","sequence":"additional","affiliation":[{"name":"Octapharma France, Boulogne-Billancourt, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Chassany","sequence":"additional","affiliation":[{"name":"University Paris-Diderot, Patient-Centered Outcomes Research, Paris"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,2]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s11940-003-0025-9","article-title":"Dermatomyositis and polymyositis","volume":"5","author":"Briemberg","year":"2003","journal-title":"Curr Treat Options Neurol"},{"issue":"(Pt 2)","key":"R2-20230915","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1016\/j.lpm.2011.01.005","article-title":"Pathophysiology of inflammatory and autoimmune myopathies","volume":"40","author":"Dalakas","year":"2011","journal-title":"Presse Med"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1183\/09031936.03.00026703","article-title":"Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis","volume":"22","author":"Cottin","year":"2003","journal-title":"Eur Respir J"},{"issue":"(Suppl 4)","key":"R4-20230915","doi-asserted-by":"crossref","first-page":"iv18","DOI":"10.1093\/rheumatology\/kel311","article-title":"The heart in dermatomyositis and polymyositis","volume":"45","author":"Lundberg","year":"2006","journal-title":"Rheumatology (Oxford)"},{"issue":"(Pt 1)","key":"R5-20230915","first-page":"934","article-title":"Dermatomyositis and polymyositis [in French]","volume":"158","author":"Pellissier","year":"2002","journal-title":"Rev Neurol (Paris)"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s10067-011-1840-0","article-title":"Survival analysis of patients with dermatomyositis and polymyositis: analysis of 192 Chinese cases","volume":"30","author":"Yu","year":"2011","journal-title":"Clin Rheumatol"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1212\/WNL.0b013e31824de293","article-title":"Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"78","author":"Patwa","year":"2012","journal-title":"Neurology"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1445-5994.2008.01822.x","article-title":"Idiopathic inflammatory myopathies","volume":"39","author":"Limaye","year":"2009","journal-title":"Intern Med J"},{"issue":"(Suppl 4)","key":"R9-20230915","doi-asserted-by":"crossref","first-page":"S256","DOI":"10.1007\/s10072-003-0090-6","article-title":"High-dose intravenous immunoglobulin in inflammatory myopathies: experience based on controlled clinical trials","volume":"24","author":"Dalakas","year":"2003","journal-title":"Neurol Sci"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1172\/JCI117520","article-title":"High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments","volume":"94","author":"Basta","year":"1994","journal-title":"J Clin Invest"},{"issue":"(Pt 8)","key":"R11-20230915","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1093\/brain\/awh518","article-title":"Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes","volume":"128","author":"Raju","year":"2005","journal-title":"Brain"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1006\/clim.1999.4823","article-title":"Downregulation of TGF-beta1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin","volume":"94","author":"Amemiya","year":"2000","journal-title":"Clin Immunol"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1002\/art.11346","article-title":"Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-alpha present in serum from patients with systemic lupus erythematosus","volume":"48","author":"Bayry","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.semarthrit.2016.07.014","article-title":"Critical review of the role of intravenous immunoglobulins in idiopathic inflammatory myopathies","volume":"46","author":"Anh-Tu Hoa","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3109\/s10165-011-0534-4","article-title":"Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial","volume":"22","author":"Miyasaka","year":"2012","journal-title":"Mod Rheumatol"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/0002-9343(91)90009-M","article-title":"Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients","volume":"91","author":"Cherin","year":"1991","journal-title":"Am J Med"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/jnnp.65.1.107","article-title":"Immunoglobulin therapy in inflammatory myopathies","volume":"65","author":"Mastaglia","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/art.10053","article-title":"Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients","volume":"46","author":"Cherin","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1136\/ard.61.1.37","article-title":"Cyclosporin A and intravenous immunoglobulin treatment in polymyositis\/dermatomyositis","volume":"61","author":"Danieli","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1136\/ard.2006.058644","article-title":"Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies","volume":"66","author":"Barbasso Helmers","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/s10165-007-0013-0","article-title":"Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroid-resistant polymyositis and dermatomyositis","volume":"18","author":"Saito","year":"2008","journal-title":"Mod Rheumatol"},{"key":"R23-20230915","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.autrev.2009.04.003","article-title":"Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis","volume":"9","author":"Danieli","year":"2009","journal-title":"Autoimmun Rev"},{"key":"R24-20230915","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/imj.13308","article-title":"Use of intravenous immunoglobulin therapy for myositis: an audit in South Australian patients","volume":"47","author":"Foreman","year":"2017","journal-title":"Intern Med J"},{"key":"R25-20230915","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.autrev.2014.08.023","article-title":"Impact of treatment on survival in polymyositis and dermatomyositis. A single-centre long-term follow-up study","volume":"13","author":"Danieli","year":"2014","journal-title":"Autoimmun Rev"},{"key":"R26-20230915","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.autrev.2015.12.003","article-title":"Long-term subcutaneous immunoglobulin use in inflammatory myopathies: a retrospective review of 19 cases","volume":"15","author":"Cherin","year":"2016","journal-title":"Autoimmun Rev"},{"key":"R27-20230915","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10067-013-2478-x","article-title":"Open-label study on treatment with 20% subcutaneous IgG administration in polymyositis and dermatomyositis","volume":"33","author":"Danieli","year":"2014","journal-title":"Clin Rheumatol"},{"key":"R28-20230915","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.autrev.2010.09.004","article-title":"Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application","volume":"10","author":"Danieli","year":"2011","journal-title":"Autoimmun Rev"},{"key":"R29-20230915","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/13548506.2013.793372","article-title":"Exploring quality of life in Italian patients with rare disease: a computer-aided content analysis of illness stories","volume":"19","author":"Caputo","year":"2014","journal-title":"Psychol Health Med"},{"key":"R30-20230915","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1080\/00207594.2013.806811","article-title":"Family routines and rituals in the context of chronic conditions: a review","volume":"48","author":"Crespo","year":"2013","journal-title":"Int J Psychol"},{"key":"R31-20230915","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2147\/PPA.S156983","article-title":"In-depth interviews of patients with primary immunodeficiency who have experienced pump and rapid push subcutaneous infusions of immunoglobulins reveal new insights on their preference and expectations","volume":"12","author":"Cozon","year":"2018","journal-title":"Patient Prefer Adherence"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000019012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T23:02:37Z","timestamp":1694818957000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000019012"}},"subtitle":["A qualitative research study"],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":31,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000019012","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2]]}}}